Skip to main content

Table 1 Study characteristics

From: The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review

First author, year of publication

Study design

Sample size

Sample size for RRSO

Age at time of studya, mean (range/SD)b

BRCA status (%)

Menopause status at time of RRSO (%)

Age at RRSO surgery, mean(range/SD)b

Comparator

Quality rating

Challberg, 2011 [33]

Cross-sectional survey design

212

212

50(36-77)

BRCA1 & BRCA2 (58%)

Premenopausal (100%)

41.20 (24-48)

Non-exposed and previous users

Low

Chapman, 2011 [37]

Cross-sectional survey design

51

51

49 (36-54)

BRCA1 (63%) & BRCA2 (37%)

Premenopausal (47%) & Postmenopausal (53%)

46 (31–68)

Non-exposed

Low

Eisen, 2008 [21]

Matched case control study

472

136

NS

BRCA1 (100%)

Premenopausal (100%)

42.45 (28 – 52)c

Control (no outcome)

High

Finch, 2011 [38]

Prospective cohort study

114

114

53(42-74)

BRCA1 (51%) & BRCA2 (49%)

Premenopausal (66%) & Postmenopausal (34%)

47.50 (35-69)

Non-exposed, baseline

Low

Gabriel, 2008 [28]

Retrospective cohort study

73

73

NS

BRCA1 (64%) & BRCA2 (38%)

Premenopausal (NS) & Postmenopausal (NS)

42 (29.5-59.2)

Non-exposed

Low

Garcia, 2015 [30]

Retrospective chart review

225

225

NS

BRCA1 & 2 (100%)

Premenopausal (NS) & Postmenopausal (NS)

50 (31-80)

Non-exposed

Low

Heiniger, 2014 [29]

Matched prospective cohort design

233

38

NS

BRCA1 & 2 (16.7%)

Premenopausal (NS) & Postmenopausal (NS)

NS

Non-exposed and previous users

Low

Johansen, 2016 [36]

Retrospective cohort study

1522

294

54(33-83)

NSd

Premenopausal (NS) & Postmenopausal (NS)

48(31-76)

Non-exposed

Low

Kotsopoulos, 2016 [31]

Matched case control study

864

210

NS

BRCA 1 (100%)

Premenopausal (NS) & Postmenopausal (NS)

42.75(28-53)c

Control (no outcome)

Low

Madalinska, 2006 [34]

Cross-sectional survey design

450

450

46 ± 6 (range34-59)

BRCA1 & 2 (48%)

Premenopausal (100%)

43 ± 6

Non-exposed

High

Michelsen, 2009 [35]

Cross-sectional survey design

1956

326

54.4(8.9)

BRCA1 & 2 (20%)

Premenopausal (NS) & Postmenopausal (NS)

48 ± 7.8

Non-exposed

High

Rebbeck, 2005 [20]

Prospective cohort study

462

155

42.7(37-78)

BRCA1 (70%) & BRCA2 (30%)

Premenopausal (NS) & Postmenopausal (NS)

NS

Non-exposed

High

Tucker, 2016 [32]

Cross-sectional survey design

119

119

NS

BRCA1 (8.40%) & BRCA2 (11.70%)

Premenopausal (43%) & Postmenopausal (57%)

50(33-69)

Non-exposed

Low

  1. NS Not specified, RRSO Risk-reducing salpingo-oophorectomy
  2. afor RRSO cohort only; bbased on the measure of variance reported in the primary study; caverage age at surgery among cases and controls; dBRCA status is captured in the questionnaire but not reported in paper